Theravance Biopharma (NASDAQ: TBPH) returns to profit and weighs options
Rhea-AI Filing Summary
Theravance Biopharma reported a sharp turnaround for 2025, with revenue rising to $107.5M from $64.4M and net income improving to $105.9M from a $56.4M loss in 2024. Q4 revenue was $45.9M and net income $61.0M.
YUPELRI® remained the core driver, with 2025 net sales of $266.6M (Viatris-reported) versus $238.6M in 2024. The company is winding down R&D, cutting G&A about 50%, and expects operating expenses to fall about 60% from 2025’s $111.1M, targeting $60–70M of annualized cash flow from Q3 2026.
A Board Strategic Review Committee of independent directors, advised by Lazard, is urgently evaluating alternatives, including a potential sale of the company, following the CYPRESS study not meeting its primary endpoint and the wind-down of the ampreloxetine program.
Positive
- Return to profitability: 2025 net income reached $105.9M versus a $56.4M loss in 2024, with Q4 net income of $61.0M and total revenue up to $107.5M from $64.4M.
- Strong YUPELRI performance and cash outlook: YUPELRI 2025 net sales rose to $266.6M, and after a roughly 60% operating expense reduction, management targets $60–70M of annualized cash flow starting in Q3 2026.
Negative
- R&D wind-down and workforce cuts: The company plans to completely wind down its R&D organization and reduce G&A headcount by about 50%, impacting roughly half the workforce and incurring $5–7M in severance costs.
- Strategic uncertainty after trial setback: Following the CYPRESS study not meeting its primary endpoint and the ampreloxetine program wind-down, a Strategic Review Committee is urgently evaluating alternatives, including a possible sale, creating uncertainty over the long-term standalone strategy.
Insights
Theravance shifts to a cash-generating YUPELRI-focused model while exploring a possible sale.
Theravance Biopharma delivered a strong financial swing in 2025, moving from a $56.4M net loss to $105.9M net income, helped by YUPELRI collaboration revenue, licensing income, and a $50M TRELEGY milestone. Core YUPELRI net sales grew to $266.6M.
The company is effectively exiting R&D and materially shrinking G&A, expecting about a 60% cut in operating expenses versus 2025’s $111.1M. Management projects $60–70M of annualized cash flow from Q3 2026, based mainly on YUPELRI economics and investment income, excluding any further TRELEGY milestone receipts.
The Board’s Strategic Review Committee, with Lazard as advisor, is reviewing "a broad range" of tax-efficient alternatives, explicitly including a potential sale. The loss of pipeline from the ampreloxetine wind-down reduces long-term organic growth options, so future disclosures about the review’s outcome will be important for understanding the company’s direction.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of | (Commission File Number) | (I.R.S. Employer Identification | ||
| Incorporation) | Number) |
(
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On March 19, 2026, Theravance Biopharma, Inc. (the “Company”) issued a press release regarding its financial results for the quarter and full year ended December 31, 2025 and a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
The information in Item 2.02 and in Item 9.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press Release dated March 19, 2026 |
| 104 | Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| THERAVANCE BIOPHARMA, INC. | ||
| Date: March 19, 2026 | By: | /s/ Aziz Sawaf |
| Aziz Sawaf | ||
| Senior Vice President and Chief Financial Officer | ||
Exhibit 99.1
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025
Financial Results and Provides Corporate Update
| · | Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starting in Q3 2026 |
| · | Strategic Review Committee accelerating evaluation of opportunities to maximize shareholder value |
| · | YUPELRI® achieved record brand profitability for Q4 and full-year 2025; full-year net sales of $266.6 million, recognized by Viatris, up 12% year-over-year1 resulting in a $25 million milestone payment |
| · | Full-year 2025 TRELEGY net sales, reported by GSK, of $3.9 billion, up 12% year-over-year, triggered a $50 million milestone payment; high confidence in achieving the $100 million 2026 milestone payment2 |
| · | All-time high non-GAAP profitability achieved for the second consecutive quarter3 |
| · | Company expects to have approximately $400 million in cash at the end of Q1 2026 and no debt |
DUBLIN, IRELAND – March 19, 2026 – Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today reported financial and operational results for the fourth quarter and full year of 2025.
"We ended 2025 on a positive note from a financial perspective, achieving another record quarter of non-GAAP profitability, hitting a new all-time high for YUPELRI® brand-level profitability, and reaching $75 million in key sales-based milestones. These results highlight the strength and durability of our commercial asset, YUPELRI®, our commitment to operating with financial and operational discipline, and the strength of our balance sheet,” said Rick E Winningham, Chief Executive Officer of Theravance Biopharma. “Since announcing the CYPRESS study results earlier this month, we have made progress implementing an organizational restructuring to streamline costs and align resources with the commercial opportunity ahead of YUPELRI®. We are confident that these actions, paired with the important work that the Board’s Strategic Review Committee is doing to evaluate opportunities available to the Company, will enable Theravance to deliver on our goal of maximizing value for shareholders.”
Strategic Review Committee
In 2024, the Theravance Board of Directors formed a Strategic Review Committee (the “Committee”) composed entirely of independent directors to assess all strategic alternatives available to the Company. Since then, the Committee has been working on an ongoing basis with Lazard, its independent financial advisor, to evaluate opportunities to maximize shareholder value, including under multiple potential outcomes for the CYPRESS study, which the Company announced on March 3rd did not meet the primary endpoint. Building upon this work, the Committee is acting with urgency to evaluate a broad range of value maximizing and tax efficient alternatives, including but not limited to a sale of the Company. In connection with the Company’s March 3rd announcement to wind down the ampreloxetine program and implement an organizational restructuring, the Committee has accelerated its evaluation of strategic alternatives for the Company. There can be no assurance that the Committee’s strategic review process will result in any transaction. Theravance Biopharma does not intend to disclose further developments on this review process unless and until it determines that such disclosure is appropriate or necessary.
1 In the U.S., Viatris is leading the commercialization of YUPELRI, and the Company co-promotes the product under a profit and loss sharing arrangement (65% to Viatris; 35% to the Company).
2 Payment from Royalty Pharma (RP) will be triggered if RP receives certain minimum royalty payments from GSK based on TRELEGY global net sales.
3 Non-GAAP profit (loss) consists of GAAP net income (loss) before taxes less (i) share-based compensation expense, (ii) non-cash interest expense, and (iii) non-recurring revenue and income items. See the section titled "Non-GAAP Financial Measures" for more information.
Page 1 of 9
Operational Highlights
YUPELRI® (revefenacin) inhalation solution, the first and only once-daily, nebulized LAMA (long-acting muscarinic antagonist) bronchodilator approved in the U.S. for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD):
| · | Annual U.S. net sales of $266.6 million, increasing 12% year-over-year (YoY) (FY 2025 vs FY 2024)1 triggered $25 million sales-based milestone from VIATRIS with cash received in January 2026. |
| · | Quarterly U.S. net sales of $70.6 million in Q4 2025, increasing 6% year-over-year (YoY) (Q4 2025 vs Q4 2024)1 driven by strong customer demand growth of 14% YoY (Q4 2025 vs Q4 2024)4, offset by timing of customer purchasing patterns. |
| · | Increased doses pulled through the hospital channel by 13% YoY (Q4 2025 vs Q4 2024), reflecting another solid quarter of growth.5 |
TRELEGY
GSK reported fourth quarter 2025 global net sales of approximately $970 million (up 14% vs. the fourth quarter of 2024) and full year net sales of approximately $3.9 billion (up 13% vs. full year 2024)6:
| · | FY 2025 global net sales of approximately $3.9 billion triggered a $50M milestone payment from Royalty Pharma, with cash received in February 2026. |
| · | FY 2026 global net sales of ~$3.5 billion required to trigger an additional $100M milestone payment from Royalty Pharma. |
4 Source: Viatris Customer Demand (Q3’25).
5 Source: IQVIA DDD, HDS, VA and Non-Reporting Hospital through Sept ’25.
6 GSK-reported Net Sales in USD.
Page 2 of 9
Organizational Restructuring Update
| · | Following the announcement of the Company’s Phase 3 CYPRESS results, Theravance has made progress on its organizational restructuring. |
| · | The wind-down of the R&D organization is underway and is expected to be largely complete by the beginning of the third quarter of 2026. |
| · | The Company reaffirms it is on track to reduce operating expenses by approximately 60%, resulting in approximately $60 - $70 million of annualized cash flow, with the full benefit expected to be realized beginning in the third quarter of 2026. |
Fourth Quarter Financial Results
| · | Revenue: Total revenue for the fourth quarter of 2025 was $45.9 million, consisting of $20.9 million of Viatris collaboration revenue and $25.0 million of licensing and milestone revenue related to the achievement of the 2025 full-year sales-based milestone for YUPELRI. Viatris collaboration revenue increased by $2.1 million, or 11%, in the fourth quarter compared to the same period in 2024. The Viatris collaboration revenue represents amounts receivable from Viatris and comprises the Company’s 35% share of net sales of YUPELRI, as well as its proportionate amount of the total shared commercial costs incurred by the two companies. The non-shared YUPELRI costs incurred by Theravance Biopharma are recorded within operating expenses. While Viatris records the total net sales of YUPELRI within its financial statements, Theravance Biopharma’s implied 35% share of net sales of YUPELRI for the fourth quarter of 2025 was $24.7 million which represented a 6% increase compared to the same period in 2024. |
| · | Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2025 were $7.4 million, compared to $9.5 million in the same period in 2024. The reduction was driven by the near completion of the CYPRESS clinical trial. Fourth quarter R&D expenses included total non-cash share-based compensation of $1.0 million. In terms of Financial Guidance, full year 2025 R&D expenses excluding non-cash share-based compensation were $33.3 million which was within our Financial Guidance of $32 million to $38 million. |
| · | Selling, General and Administrative (SG&A) Expenses: SG&A expenses for the fourth quarter of 2025 were $18.5 million and were unchanged compared to the same period in 2024. Fourth quarter SG&A expenses included total non-cash share-based compensation of $3.5 million. In terms of Financial Guidance, full year 2025 SG&A expenses excluding non-cash share-based compensation were $59.3 million which was within our Financial Guidance of $50 million to $60 million. |
| · | Share-Based Compensation: Share-based compensation expenses for the fourth quarter of 2025 were $4.5 million, compared to $5.8 million in the same period in 2024. Share-based compensation expenses consisted of $1.0 million for R&D and $3.5 million for SG&A in the fourth quarter of 2025, compared to $1.4 million and $4.4 million, respectively, in the same period in 2024. In terms of Financial Guidance, full year 2025 share-based compensation expenses were $18.5 million which was within our Financial Guidance of $18 million to $20 million. |
Page 3 of 9
| · | TRELEGY Milestone Income: The Company recognized $50.0 million in milestone income in the fourth quarter of 2025 triggered by achieving the 2025 TRELEGY net sales threshold. |
| · | Income Taxes: Income tax expense for the fourth quarter of 2025 was $12.0 million, compared to a $6.6 million income tax expense in the same period in 2024. The increase was primarily due to taxes on the $50.0 million TRELEGY milestone income recognized in the fourth quarter of 2025. |
| · | Net Income: Net income was $61.0 million in the fourth quarter of 2025 compared to a net loss of $15.5 million in the same period in 2024. The net income benefited from achieving the $25.0 million and $50.0 million YUPELRI and TRELEGY 2025 net sales milestones, respectively. |
| · | Non-GAAP Net Income (Loss) from Operations3: Non-GAAP net income from operations was $3.1 million in the fourth quarter of 2025 compared to a non-GAAP net loss from operations of $2.5 million in the same period in 2024. See the section titled "Non-GAAP Financial Measures" for more information. |
| · | Cash Position: Cash, cash equivalents and marketable securities totaled $326.5 million as of December 31, 2025. The Company received a $25.0 million YUPELRI U.S. sales milestone from Viatris in January 2026 and a $50.0 million TRELEGY milestone from Royalty Pharma in February 2026. Taking into account the TRELEGY and YUPELRI milestones received in the first quarter of 2026, the Company expects to have approximately $400.0 million in cash, cash equivalents and marketable securities at the end of the first quarter of 2026. |
| · | Shares Outstanding: The Company had 51,068,545 ordinary shares outstanding as of December 31, 2025. |
2026 Financial Guidance
Theravance Biopharma is implementing an organizational restructuring to streamline costs and align its resources with its commercial focus on YUPELRI. The restructuring will involve winding down the R&D function and significantly reducing the G&A function. The restructuring is expected to reduce operating expenses by approximately 60%, relative to 2025 actuals of $111.1 million. The full run-rate cost savings of approximately $70 million are expected to fully materialize in the third quarter of 2026.
Together, the cost savings from the restructuring and continued sales from YUPELRI are expected to result in the Company generating approximately $60 to $70 million of annualized cash flow, starting in the third quarter of 2026. This cash flow projection is comprised of an estimated $45 to $55 million of Income from Operations (excluding non-cash share-based compensation) and projected Interest and Other Income, and does not include potential income from the $100 million TRELEGY milestone.
Page 4 of 9
The restructuring is expected to impact approximately 50% of the overall workforce. This reduction includes the complete wind-down of the R&D organization and a decrease of approximately 50% in G&A employees. These actions are expected to be implemented over the next two quarters, and the Company expects to incur approximately $5 to $7 million in one-time cash severance costs related to these actions.
Conference Call
Beginning with this quarter, earnings results will be released via press release only. The Company will not host a conference call or webcast to discuss quarterly results.
About Theravance Biopharma
Theravance Biopharma, Inc.’s focus is to deliver Medicines that Make a Difference® in people’s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Page 5 of 9
Forward-Looking Statements
This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations and future events. Theravance Biopharma, Inc. (the “Company”) intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: the Company’s expectations regarding its future profitability, expenses and uses of cash, the Company’s goals, designs, strategies, plans and objectives, future growth of YUPELRI sales and future royalty payments, the winddown of the Company’s ampreloxetine program and R&D function and significant reduction of its G&A function, the consideration of strategic alternatives for the Company, the ability to provide value to shareholders, the Company’s regulatory strategies, the status of patent infringement litigation initiated by the Company and its partner against certain generic companies in federal district courts, and contingent milestone payments due to the Company from the sale of the Company’s TRELEGY royalty interests. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: factors that could increase the Company’s expenses beyond its expectations and any factors that could adversely affect its profitability, whether the TRELEGY milestone thresholds will be achieved, delays or difficulties in winding down clinical studies, the timing of any potential strategic transaction with respect to the Company, if at all, risks of collaborating with or relying on third parties to develop, manufacture and commercialize products, and risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate technical expertise and supporting infrastructure, the ability of the Company to protect and to enforce its intellectual property rights, volatility and fluctuations in the trading price and volume of the Company’s shares, and general economic and market conditions. Other risks affecting the Company are in the Company’s Form 10-Q filed with the SEC on November 12, 2025, and other periodic reports filed with the SEC. In addition to the risks described above and in Theravance Biopharma's filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma’s results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.
Non-GAAP Financial Measures
Theravance Biopharma provides a non-GAAP metric in this press release. Theravance Biopharma believes that non-GAAP net income (loss) provides meaningful information to assist investors in assessing prospects for future performance and actual performance as they provide better metrics for analyzing the performance of its business by excluding items that may not be indicative of core operating results and the Company's cash position. Because non-GAAP financial targets and metrics, such as non-GAAP net income (loss), are not standardized, it may not be possible to compare these measures with other companies' non-GAAP targets or measures having the same or a similar name. Thus, Theravance Biopharma's non-GAAP measures should be considered in addition to, not as a substitute for, or in isolation from, the Company's actual GAAP results and other targets.
Please see the appendix attached to this press release for a reconciliation of non-GAAP net income (loss) to its corresponding measure, net income (loss). A reconciliation of non-GAAP net income (loss) to its corresponding GAAP measure is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding, and the potential variability of, expenses and other factors in the future.
Contact:
investor.relations@theravance.com
650-808-4045
Page 6 of 9
THERAVANCE BIOPHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| (Unaudited) | (1) | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents and short-term marketable securities | $ | 315,357 | $ | 88,350 | ||||
| Receivables from collaborative arrangements | 45,539 | 18,440 | ||||||
| Receivables from milestone and royalty assets | 50,000 | 50,000 | ||||||
| Other prepaid and current assets | 7,564 | 4,277 | ||||||
| Total current assets | 418,460 | 161,067 | ||||||
| Long-term marketable securities | 11,128 | - | ||||||
| Property and equipment, net | 5,895 | 7,418 | ||||||
| Operating lease assets | 24,371 | 28,354 | ||||||
| Future contingent milestone and royalty assets | - | 144,200 | ||||||
| Restricted cash | 836 | 836 | ||||||
| Other assets | 24,880 | 12,286 | ||||||
| Total assets | $ | 485,570 | $ | 354,161 | ||||
| Liabilities and Shareholders' Equity | ||||||||
| Current liabilities | $ | 38,302 | $ | 32,085 | ||||
| Long-term operating lease liabilities | 31,758 | 39,108 | ||||||
| Future royalty payment contingency | 32,795 | 30,334 | ||||||
| Unrecognized tax benefits | 85,679 | 75,199 | ||||||
| Other long-term liabilities | 313 | 1,890 | ||||||
| Shareholders' equity | 296,723 | 175,545 | ||||||
| Total liabilities and shareholders’ equity | $ | 485,570 | $ | 354,161 | ||||
| (1) | The condensed consolidated balance sheet as of December 31, 2024 has been derived from the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. |
Page 7 of 9
THERAVANCE BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||||||
| Revenue: | ||||||||||||||||
| Viatris collaboration agreement (1) | $ | 20,891 | $ | 18,754 | $ | 74,964 | $ | 64,381 | ||||||||
| Licensing and milestone revenue | 25,000 | - | 32,500 | - | ||||||||||||
| Total revenue | 45,891 | 18,754 | 107,464 | 64,381 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Research and development (2) | 7,362 | 9,452 | 37,414 | 37,643 | ||||||||||||
| Selling, general and administrative (2) | 18,517 | 18,502 | 73,652 | 69,174 | ||||||||||||
| Impairment of long-lived assets (non-cash) | - | - | - | 4,513 | ||||||||||||
| Total costs and expenses | 25,879 | 27,954 | 111,066 | 111,330 | ||||||||||||
| Income (loss) from operations | 20,012 | (9,200 | ) | (3,602 | ) | (46,949 | ) | |||||||||
| Net gain on realized contingent milestone and royalty assets | - | - | 75,137 | - | ||||||||||||
| TRELEGY milestone income | 50,000 | - | 50,000 | - | ||||||||||||
| Interest expense (non-cash) | (583 | ) | (643 | ) | (2,461 | ) | (2,546 | ) | ||||||||
| Interest income and other income, net | 3,640 | 902 | 10,173 | 4,881 | ||||||||||||
| Income (loss) before income taxes | 73,069 | (8,941 | ) | 129,247 | (44,614 | ) | ||||||||||
| Provision for income tax expense | (12,045 | ) | (6,587 | ) | (23,352 | ) | (11,804 | ) | ||||||||
| Net income (loss) | $ | 61,024 | $ | (15,528 | ) | $ | 105,895 | $ | (56,418 | ) | ||||||
| Net income (loss) per share: | ||||||||||||||||
| Net income (loss) per share - basic | $ | 1.20 | $ | (0.31 | ) | $ | 2.10 | $ | (1.15 | ) | ||||||
| Net income (loss) per share - diluted | $ | 1.15 | $ | (0.31 | ) | $ | 2.06 | $ | (1.15 | ) | ||||||
| Shares used to compute net income (loss) per share - basis | 50,868 | 49,306 | 50,317 | 48,847 | ||||||||||||
| Shares used to compute net income (loss) per share - diluted | 53,053 | 49,306 | 51,507 | 48,847 | ||||||||||||
| Non-GAAP net income (loss) | $ | 3,131 | $ | (2,472 | ) | $ | (7,453 | ) | $ | (16,162 | ) | |||||
| (1) | While Viatris, Inc. records the total YUPELRI net sales, the Company is entitled to a 35% share of the net profit (loss) pursuant to a co-promotion agreement with Viatris as presented below: |
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| (In thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| YUPELRI net sales (100% recorded by Viatris) | $ | 70,563 | $ | 66,680 | $ | 266,600 | $ | 238,626 | ||||||||
| YUPELRI net sales (Theravance Biopharma implied 35%) | 24,697 | 23,339 | 93,310 | 83,520 | ||||||||||||
| (2) | Amounts include share-based compensation expense as follows: |
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| (In thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Research and development | $ | 944 | $ | 1,377 | $ | 4,081 | $ | 5,104 | ||||||||
| Selling, general and administrative | 3,535 | 4,449 | 14,395 | 16,289 | ||||||||||||
| Total share-based compensation expense | $ | 4,479 | $ | 5,826 | $ | 18,476 | $ | 21,393 | ||||||||
Page 8 of 9
THERAVANCE BIOPHARMA, INC.
Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Income (Loss)
(In thousands)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||||||
| GAAP net income (loss) | $ | 61,024 | $ | (15,528 | ) | $ | 105,895 | $ | (56,418 | ) | ||||||
| Adjustments: | ||||||||||||||||
| Licensing revenue (1) | (25,000 | ) | - | (32,500 | ) | - | ||||||||||
| Net gain on realized contingent milestone and royalty assets (1) | - | - | (75,137 | ) | - | |||||||||||
| TRELEGY milestone income (1) | (50,000 | ) | (50,000 | ) | ||||||||||||
| Non-cash impairment expense of long-lived assets (1) | - | - | - | 4,513 | ||||||||||||
| Share-based compensation expense | 4,479 | 5,826 | 18,476 | 21,393 | ||||||||||||
| Non-cash interest expense | 583 | 643 | 2,461 | 2,546 | ||||||||||||
| Income tax expense | 12,045 | 6,587 | 23,352 | 11,804 | ||||||||||||
| Non-GAAP net income (loss) | $ | 3,131 | $ | (2,472 | ) | $ | (7,453 | ) | $ | (16,162 | ) | |||||
| (1) | Non-recurring item |
Page 9 of 9
FAQ
How did Theravance Biopharma (TBPH) perform financially in 2025?
What were Theravance Biopharma’s Q4 2025 results?
How is YUPELRI contributing to Theravance Biopharma’s results?
What cost-cutting and restructuring actions is Theravance Biopharma taking?
What is Theravance Biopharma’s projected cash flow after restructuring?
What strategic alternatives is Theravance Biopharma considering?
Filing Exhibits & Attachments
4 documents